Computational Systems Pharmacology and Toxicology

2017 ◽  
Keyword(s):  
Systems Pharmacology ◽  
Pharmacology And Toxicology ◽  
Computational Systems

scholarly journals Computational Systems Pharmacology-Target Mapping for Fentanyl-Laced Cocaine Overdose

2019 ◽  
Vol 10 (8) ◽  
pp. 3486-3499 ◽  
Author(s):  
Jin Cheng ◽  
Siyi Wang ◽  
Weiwei Lin ◽  
Nan Wu ◽  
Yuanqiang Wang ◽  
...  
Keyword(s):  
Systems Pharmacology ◽  
Computational Systems

scholarly journals A quantitative systems pharmacology analysis of KRAS G12C covalent inhibitors

2017 ◽  
Author(s):  
Edward C. Stites ◽  
Andrey S. Shaw
Keyword(s):  
Human Cancer ◽  
Conventional Wisdom ◽  
Ras Signaling ◽  
Systems Pharmacology ◽  
Ras Pathway ◽  
Ras Protein ◽  
Oncogenic Mutation ◽  
Ras Activation ◽  
Covalent Inhibitors ◽  
Computational Systems

AbstractThe KRAS oncogene is the most common, activating, oncogenic mutation in human cancer. KRAS has proven difficult to target effectively. Two different strategies have recently been described for covalently targeting the most common activating KRAS mutant in lung cancer, KRAS G12C. Previously, we have developed a computational model of the processes that regulate Ras activation and this model has proven useful for understanding the complex behaviors of Ras signaling. Here, we use this model to perform a computational systems pharmacology analysis of KRAS G12C targeted covalent inhibitors. After updating our model to include Ras protein turnover, we verified the validity of our model for problems in this domain by comparing model behaviors with experimental behaviors. The model naturally reproduces previous experimental data, including several experimental observations that were interpreted as being contrary to conventional wisdom. Overall, this suggests that our model describes the Ras system well, including those areas where conventional wisdom struggles. We then used the model to investigate possible strategies to improve the ability of KRAS G12C inhibitors to inhibit Ras pathway signaling. We identify one, as of yet unexplored mechanism, that, if optimized, could improve the effectiveness of one class of KRAS inhibitor. We also simulated resistance to targeted therapies and found that resistance promoting mutations may reverse which class of KRAS G12C inhibitor inhibits the system better, suggesting that there may be value to pursuing both types of KRAS G12C inhibitors. Overall, this work demonstrates that systems biology approaches can provide insights that inform the drug development process.

Sign in / Sign up

Export Citation Format

Share Document